Our Team

Trina Hazzah was born and raised in Washington DC. She attended Tuskegee University School of Veterinary Medicine where she earned her Doctor of Veterinary Medicine in 2006. She completed her small animal internship at Red Bank Veterinary Hospital in New Jersey and a 3-year residency in medical oncology at the Veterinary Oncology and Hematology Center, in Connecticut. She has also completed the requirements to be a Certified Veterinary Chinese Herbalist from the Chi Institute of Traditional Chinese Veterinary Medicine.

Dr. Hazzah developed an interest in cannabis medicine during her quest for finding effective integrative approaches for veterinary cancer patients. She has spent the last half a decade reading though available literature, attending multiple cannabis conferences and symposiums, while also learning from cannabis physicians. She has since given numerous lectures to veterinarians educating them on the topic of cannabis medicine. Dr. Hazzah is a founder and the co-president of Veterinary Cannabis Society and a member of the Society of Cannabis Clinician, Canadian Association of Veterinary Cannabinoid Medicine, Veterinary Cancer Society, American Holistic Veterinary Medical Association and California Veterinary Medical Association.

Hunter Land, PhD, MS is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Dr. Land acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world’s largest cannabis producer. Most notably, he was GW Pharma’s first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® (FDA-approved prescription CBD) and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), multiple sclerosis, and pain. Dr. Land has presented at over 50 scientific conferences, is a named inventor on nine patent applications, and has over 20 publications. In addition, he serves as a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a cannabinoid subject matter expert. Dr. Land also holds several other important positions, including Chief Scientific Officer for the National Hockey League Alumni/NEEKA Brain Health, Executive Board Member at Alterola Biotech, co-founder of the Cannabinoid Education Working Group, and member of the advisory board for the Council for Federal Cannabis Regulation.

Dr. McGrath is an Associate Professor in the Clinical Sciences Department and head of the Neurology Service at Colorado State University’s College of Veterinary Medicine and Biomedical Sciences. She received her Bachelor’s degree at Columbia University, completed the Doctor of Veterinary Medicine program at Michigan State University, and did an internship at Red Bank Veterinary Hospital. Dr. McGrath completed the neurology residency program at Colorado State University and has been a faculty member there since 2012. She is board- certified in veterinary neurology and, for the past 13 years, has been working in the highly specialized field of medical and surgical neurology. Her responsibilities include clinical duties, didactic teaching for veterinary and post-graduate students, and research activities. Dr. McGrath’s research has been dedicated to finding novel treatments for canine epilepsy, canine brain tumors, cognitive dysfunction, and canine inflammatory central nervous system diseases. For the past six years, her research efforts have been primarily focused on cannabis, both in a laboratory setting and with clinical trials utilizing client-owned animals with naturally-occurring diseases. Her groundbreaking cannabis research and expertise is highly regarded and internationally recognized. She has been successful in generating and utilizing pre-clinical data to perform clinical trials in a variety of naturally-occurring canine and feline diseases, most of which serve as a strong translational model for humans. Most recently, Dr. McGrath was granted the 2020 Zoetis Award for Research Excellence, honoring her impactful, innovative, and successful research program.

Dr. Susan Trapp is a 20-year biotechnology expert with a vision to accelerate patient-centric cannabis and endocannabinoid discoveries through education and research. She attended the University of Maryland where she earned her Ph.D. degree in Biochemistry with a focus on plant and fungal terpenoids. Dr. Trapp completed her 3-year postdoctoral educational training at the Institute of Biological Chemistry at Washington State University where she continued her research on terpenoid genomics and genetic engineering within a seminal terpenoid research laboratory. Prior to her graduate work in the early nineties, Susan had the opportunity to work directly with Dr. Craig Venter, on the human genome project which has definitely influenced her research fascination in genomics, personalized medicine, and computational biology. Susan has a number of peer-review publications, book chapters, podcasts, and presentations on terpenes, terpene genomics, human genomics, and canine, and breast cancer biomarker identification.

Dr. Trapp earned her nickname as the ‘Queen of Terpenes’ by serving as a scientific advisor and valued consultant for cannabis and hemp companies as they continue to navigate the function of terpenes in products. Motivated by her passion for education, Dr. Trapp utilizes her in-depth knowledge of terpenes to educate the cannabis community at conferences and conventions nationwide. Susan Trapp also serves as an instructor for the Cannabinoid Industry Association’s accredited courses.

Since making the shift to cannabis, Susan co-founded several ancillary cannabis companies and is a recent graduate of Canopy Boulder’s cannabis business accelerator program. Her current projects include launching two terpene and cannabinoid-focused startups: Terpedia and EndoSyn Biosciences. Dr. Trapp is a founder and CEO of Terpedia, a digital scientific terpene knowledge-base with curated data and terpene – cannabinoid consultancy. Terpedia provides recommendations, formulations, validation, and effectiveness studies. Susan is a member of the Society of Cannabis Clinicians, International Society for Plant-Microbe Interactions, and Society for Computational Biology.

A native of Shepherdsville, KY, Dr. Joli Jarboe graduated from the Auburn College of Veterinary Medicine in 1993. After spending a year in private practice and two years in a 24-hr referral hospital as an emergency clinician in Ft. Pierce, FL, she began a three-year neurology residency at the University of Missouri-Columbia and stayed on as a Clinical Instructor for another 1.5 yrs. Private practice has taken her to Houston, TX; Las Vegas, NV; Cincinnati, OH; and Leesburg, VA. She has called Leesburg, VA and Bush Veterinary Neurology home since August 2009, serving as Medical Director for 5 years and continuing on as senior Neurologist/Neurosurgeon.

She has been actively involved with the training of neurology residents and interns since completing her Neurology Residency in 1999. She is past secretary of the Veterinary Neurosurgical Society. Her clinical interests revolve around all aspects of neurosurgery with a passionate interest in brain and cervical neurosurgery. She has become renowned for her interest and support of cannabinoid therapy in veterinary medicine in the past 15 years and is a passionate proponent of this adjuvant therapy. In 2017, she aligned herself with Zilis, a cannabinoid science supplement company manufacturing Ultracell, a full spectrum water soluble phytocannabinoid supplement and currently serves on their Medical Advisory Board. She is also an active consultant for Veterinary Cannabis Education and Consulting and a member of Veterinary Cannabis Society. She is a contributing author in 2021 Springer edition of Veterinary Cannabis Therapy in Veterinary Medicine.

Dr. Zac Pilossoph is a nationally recognized Fear-Free integrative veterinarian and top graduate of Tufts Cummings School of Veterinary Medicine. He is currently a front-line medical cannabis-focused vet in the integrative and holistic medicine space, advocating for the numerous benefits cannabis-based therapies can offer to all types of animals when applied responsibly. Furthermore, Dr. Zac enjoys balancing conventional western medicine techniques with holistic-based remedies both in practice and through his private telehealth platform Nayked Pet™ in order to maximize pet health, wellness, and longevity from the very beginning of life. With integrative medicine still being a relatively novel approach to patient care, Dr. Zac is extremely excited to be at the forefront of this movement alongside a select group of colleagues who also believe in the same principles he has come to trust and uphold.

Holly Hommerding was born and raised in central Minnesota and attended the University of Minnesota College of Veterinary Medicine where she earned her bachelor’s degree in Veterinary Science in 2005 and her Doctor of Veterinary Medicine degree in 2008. Holly spent an early and fulfilling career in small animal general practice in the northern suburbs of Minneapolis through 2016, where her love for life-long patient care and preventative medicine, elder-life care, and an early interest in the potential benefits of cannabis in veterinary patients began to harmonize.

Dr. Hommerding joined Pet Poison Helpline in 2014, through which she was afforded the opportunity to specialize in veterinary toxicology. Holly became a Diplomate of the American Board of Toxicology (ABT) in 2018 and a Diplomate of the American Board of Veterinary Toxicology (ABVT) in 2022. Her work in clinical veterinary toxicology at Pet Poison Helpline has cultured and fostered an interest and appreciation for the complexities of the endocannabinoid system and the pharmacologic and clinical behavior of cannabis in companion animals. She most enjoys discussing the toxicological considerations of cannabis in pets with colleagues and animal guardians alike through consultation and lecture opportunities, and she continues to pursue knowledge in the ever growing and changing corner of this field. With gratitude to her mentors, Dr. Hommerding has most recently welcomed opportunities to share the toxicological considerations of cannabis in pets through contributions to several veterinary textbooks.

Holly lives in the Twin Cities area with her comical golden retrievers, her strong-willed cat, and her very geriatric small parrot.